{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:03:19Z","timestamp":1794744199960,"version":"4.9.1"},"reference-count":149,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSD"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"DOI":"10.13039\/100004324","name":"Astellas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi Aventis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Debiopharm","id":[{"id":"https:\/\/ror.org\/00nxzrk14","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009734","name":"Olympus","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.eururo.2020.03.055","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T07:52:19Z","timestamp":1588146739000},"page":"82-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1684,"title":["European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines"],"prefix":"10.1016","volume":"79","author":[{"given":"J. Alfred","family":"Witjes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harman Max","family":"Bruins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel C.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Gakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania","family":"Linares Espin\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Lorch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4345-3598","authenticated-orcid":false,"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Rouanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George N.","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Veskim\u00e4e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8142-5382","authenticated-orcid":false,"given":"Maria J.","family":"Ribal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8839-8601","authenticated-orcid":false,"given":"Antoine G.","family":"van der Heijden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2020.03.055_bib0005","unstructured":"Phillips B, Ball C, Sackett D, et al. Oxford Centre for Evidence-based Medicine levels of evidence. Updated by Jeremy Howick; March 2009. https:\/\/www.cebm.net\/2009\/06\/oxford-centre-evidence-based-medicine-levels-evidence-march-2009\/ [accessed April 24, 2020]."},{"key":"10.1016\/j.eururo.2020.03.055_bib0010","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2020.03.055_bib0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2020.03.055_bib0020","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","article-title":"EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees","volume":"77","author":"Witjes","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0025","first-page":"223","article-title":"EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees","volume":"77","author":"Horwich","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0030","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer","volume":"71","author":"Witjes","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2020.03.055_bib0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/(SICI)1097-0215(20000415)86:2<289::AID-IJC21>3.0.CO;2-M","article-title":"Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies","volume":"86","author":"Brennan","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0045","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ijrobp.2011.08.034","article-title":"Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer","volume":"83","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.03.055_bib0050","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/bjc.2014.459","article-title":"Flavonoid and lignan intake in relation to bladder cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study","volume":"111","author":"Zamora-Ros","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0055","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1002\/ijc.31597","article-title":"Risk of bladder cancer by disease severity in relation to metabolic factors and smoking: a prospective pooled cohort study of 800,000 men and women","volume":"143","author":"Teleka","year":"2018","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.cegh.2017.08.002","article-title":"Pioglitazone and risk of bladder cancer in type 2 diabetes mellitus patients: a systematic literature review and meta-analysis of observational studies using real-world data","volume":"6","author":"Adil","year":"2018","journal-title":"Clin Epidemiol Global Health"},{"key":"10.1016\/j.eururo.2020.03.055_bib0065","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00240-017-1033-7","article-title":"The risk of bladder cancer in patients with urinary calculi: a meta-analysis","volume":"46","author":"Yu","year":"2018","journal-title":"Urolithiasis"},{"key":"10.1016\/j.eururo.2020.03.055_bib0070","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00345-018-2257-z","article-title":"Role of urinary tract infection in bladder cancer: a systematic review and meta-analysis","volume":"36","author":"Bayne","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5489\/cuaj.2927","article-title":"Is there a gender effect in bladder cancer? A population-based study of practice and outcomes","volume":"9","author":"Patafio","year":"2015","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.eururo.2020.03.055_bib0080","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejca.2018.03.001","article-title":"Bladder cancer survival: Women better off in the long run","volume":"95","author":"Andreassen","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0085","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.eururo.2012.10.008","article-title":"A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens","volume":"63","author":"Hansel","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0090","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euo.2019.09.003","volume":"2","author":"Veskimae","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0095","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euf.2018.01.003","article-title":"Grading of urothelial carcinoma and the new \u201cWorld Health Organisation Classification of Tumours of the urinary system and male genital organs 2016\u201d","volume":"5","author":"Comperat","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2020.03.055_bib0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.urolonc.2009.12.020","article-title":"Discrepancy between clinical staging through bimanual palpation and pathological staging after cystectomy","volume":"30","author":"Ploeg","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0105","series-title":"Guidelines on non-muscle-invasive bladder cancer (Ta, T1 and CIS)","author":"Babjuk","year":"2020"},{"key":"10.1016\/j.eururo.2020.03.055_bib0110","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1148\/radiol.2017171028","article-title":"The diagnostic value of MR imaging in differentiating T staging of bladder cancer: a meta-analysis","volume":"286","author":"Huang","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2020.03.055_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000318985","article-title":"Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society","volume":"85","author":"Heidenreich","year":"2010","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2020.03.055_bib0120","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/annonc\/mdq398","article-title":"Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20\/99]","volume":"22","author":"Albers","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0125","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.euf.2017.08.005","article-title":"Comparative perioperative outcomes in septuagenarians and octogenarians undergoing radical cystectomy for bladder cancer\u2014do outcomes differ?","volume":"4","author":"Haden","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2020.03.055_bib0130","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/jcsm.12279","article-title":"Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer","volume":"9","author":"Mayr","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.eururo.2020.03.055_bib0135","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cncr.25345","article-title":"A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer","volume":"117","author":"Lughezzani","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0140","doi-asserted-by":"crossref","first-page":"E222","DOI":"10.1111\/j.1464-410X.2012.10938.x","article-title":"Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder","volume":"110","author":"Mayr","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.03.055_bib0145","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.juro.2011.04.089","article-title":"Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy","volume":"186","author":"Morgan","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0150","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1245\/s10434-011-1852-7","article-title":"Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study","volume":"19","author":"Abdollah","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0155","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/cncr.23462","article-title":"Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer","volume":"112","author":"Koppie","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0160","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/j.1464-410X.2010.09417.x","article-title":"Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival","volume":"106","author":"Bolenz","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.03.055_bib0165","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.eururo.2012.03.057","article-title":"Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder","volume":"62","author":"Mayr","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.06.009","article-title":"Effect of tumor location on survival in urinary bladder adenocarcinoma: a population-based analysis","volume":"34","author":"Dutta","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0175","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12885-015-1448-x","article-title":"Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis","volume":"15","author":"Ku","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrurol.2016.126","article-title":"The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder","volume":"13","author":"Mathieu","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0185","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.juro.2018.05.162","article-title":"Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: a systematic review and meta-analysis","volume":"201","author":"Kimura","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0190","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1159\/000489152","article-title":"Pretreatment neutrophil-lymphocyte ratio as a predictor in bladder cancer and metastatic or unresectable urothelial carcinoma patients: a pooled analysis of comparative studies","volume":"46","author":"Wu","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.eururo.2020.03.055_bib0195","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/cncr.30422","article-title":"Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: assessing prognostic and predictive value in SWOG 8710","volume":"123","author":"Ojerholm","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0200","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0205","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2018.09.002","article-title":"Genomic differences between \"primary\" and \"secondary\" muscle-invasive bladder cancer as a basis for disparate outcomes to cisplatin-based neoadjuvant chemotherapy","volume":"75","author":"Pietzak","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0210","doi-asserted-by":"crossref","unstructured":"Motterle G, Andrews JR, Morlacco A, Karnes RJ. Predicting response to neoadjuvant chemotherapy in bladder cancer. Eur Urol Focus. In press. https:\/\/doi.org\/10.1016\/j.euf.2019.10.016.","DOI":"10.1016\/j.euf.2019.10.016"},{"key":"10.1016\/j.eururo.2020.03.055_bib0215","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0220","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0225","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0230","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2011.05.045","article-title":"Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review","volume":"60","author":"van den Bosch","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0235","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0240","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.eururo.2003.09.019","article-title":"Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies","volume":"45","author":"Sherif","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0245","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.eururo.2020.03.055_bib0250","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/cncr.29387","article-title":"Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer","volume":"121","author":"Galsky","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0255","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"Griffiths","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0260","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","article-title":"Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer","volume":"4","author":"Peyton","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0265","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.euo.2018.02.007","article-title":"Neoadjuvant dose-dense gemcitabine and cisplatin in muscle-invasive bladder cancer: results of a phase 2 trial","volume":"1","author":"Anari","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0270","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euo.2018.03.001","article-title":"Effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the current real world setting in the USA","volume":"1","author":"Hanna","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0275","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2020.03.055_bib0280","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/00365590902854313","article-title":"Downstaging and survival benefits of neoadjuvant radiotherapy before cystectomy for patients with invasive bladder carcinoma","volume":"43","author":"Granfors","year":"2009","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0285","doi-asserted-by":"crossref","first-page":"459","DOI":"10.2147\/CMAR.S69055","article-title":"Survival benefit of adjuvant radiotherapy in stage III and IV bladder cancer: results of 170 patients","volume":"6","author":"Bayoumi","year":"2014","journal-title":"Cancer Manage Res"},{"key":"10.1016\/j.eururo.2020.03.055_bib0290","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/cncr.24052","article-title":"Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis","volume":"115","author":"Gore","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2015.11.006","article-title":"The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: a Netherlands Cancer Registry analysis","volume":"34","author":"Bruins","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0300","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1464-410X.2008.08084_1.x","article-title":"A delay in radical cystectomy of &3 months is not associated with a worse clinical outcome","volume":"102","author":"Ayres","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.03.055_bib0305","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.juro.2013.08.019","article-title":"A new concept for early recovery after surgery for patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study","volume":"191","author":"Karl","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0310","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.juro.2015.05.083","article-title":"Postoperative pain management after radical cystectomy: comparing traditional versus enhanced recovery protocol pathway","volume":"194","author":"Xu","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0315","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.eururo.2014.02.036","article-title":"Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial","volume":"66","author":"Lee","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0320","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3233\/BLC-180184","article-title":"Venous thromboembolism and peri-operative chemotherapy for muscle-invasive bladder cancer: a population-based study","volume":"4","author":"Brennan","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0325","doi-asserted-by":"crossref","first-page":"539.e17","DOI":"10.1016\/j.urolonc.2017.04.013","article-title":"Oncological and functional outcomes of sexual function-preserving cystectomy compared with standard radical cystectomy in men: a systematic review","volume":"35","author":"Hernandez","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0330","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/bju.13819","article-title":"Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer","volume":"120","author":"Veskimae","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.03.055_bib0335","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejso.2013.02.004","article-title":"Preservation of the internal genital organs during radical cystectomy in selected women with bladder cancer: a report on 15 cases with long term follow-up","volume":"39","author":"Ali-El-Dein","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0340","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/GRF.0000000000000318","article-title":"Ovarian cancer prevention in high-risk women","volume":"60","author":"Temkin","year":"2017","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0345","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2014.12.007","article-title":"Systematic review and cumulative analysis of perioperative outcomes and complications after robot-assisted radical cystectomy","volume":"67","author":"Novara","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0350","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.eururo.2014.12.009","article-title":"Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel","volume":"67","author":"Wilson","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0355","article-title":"Robotic versus open radical cystectomy for bladder cancer in adults","volume":"4","author":"Rai","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2020.03.055_bib0360","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eururo.2018.04.030","article-title":"Randomized trial comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: oncologic outcomes","volume":"74","author":"Bochner","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0365","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.11.019","article-title":"Port-site metastases after robot-assisted radical cystectomy: is there a publication bias?","volume":"73","author":"Jancke","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0370","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial","volume":"391","author":"Parekh","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2020.03.055_bib0375","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.juro.2017.12.045","article-title":"Outcomes of Intracorporeal urinary diversion after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium","volume":"199","author":"Hussein","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0380","article-title":"Laparoscopic versus open radical cystectomy in bladder cancer: a systematic review and meta-analysis of comparative studies","volume":"9","author":"Tang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2020.03.055_bib0385","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.eururo.2009.10.026","article-title":"A new multimodality technique accurately maps the primary lymphatic landing sites of the bladder","volume":"57","author":"Roth","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0390","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.eururo.2011.07.012","article-title":"Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study","volume":"60","author":"Dorin","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0395","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.eururo.2014.05.031","article-title":"The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review","volume":"66","author":"Bruins","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0400","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.eururo.2018.09.047","article-title":"Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial","volume":"75","author":"Gschwend","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0405","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.juro.2010.05.037","article-title":"Lessons learned from 1,000 neobladders: the 90-day complication rate","volume":"184","author":"Hautmann","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0410","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/JU.0000000000000034","article-title":"Positive pre-cystectomy biopsies of the prostatic urethra or bladder neck do not necessarily preclude orthotopic bladder substitution","volume":"201","author":"Roth","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0415","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1046\/j.1464-410X.2003.04000.x","article-title":"Metabolic and functional consequences of urinary reconstruction with bowel","volume":"91","author":"Gerharz","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.03.055_bib0420","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S0302-2838(02)00320-2","article-title":"After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer?","volume":"42","author":"Lebret","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0425","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/iju.12770","article-title":"Comparative impact of continent and incontinent urinary diversion on long-term renal function after radical cystectomy in patients with preoperative chronic kidney disease 2 and chronic kidney disease 3a","volume":"22","author":"Gershman","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0430","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bju.13462","article-title":"Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy","volume":"118","author":"Longo","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.03.055_bib0435","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000367853","article-title":"Impact of the use of bowel for urinary diversion on perioperative complications and 90-day mortality in patients aged 75 years or older","volume":"94","author":"Berger","year":"2015","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2020.03.055_bib0440","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.eururo.2007.09.008","article-title":"Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions","volume":"53","author":"Nieuwenhuijzen","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0445","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1097\/01.ju.0000051462.45388.14","article-title":"Long-term outcome of ileal conduit diversion","volume":"169","author":"Madersbacher","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0450","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00345-006-0078-y","article-title":"Continent cutaneous urinary diversion: long-term follow-up of more than 800 patients with ileocecal reservoirs","volume":"24","author":"Wiesner","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0455","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00345-006-0105-z","article-title":"Long-term results of standard procedures in urology: the ileal neobladder","volume":"24","author":"Hautmann","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0460","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium","volume":"176","author":"Shariat","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0465","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.eururo.2011.07.066","article-title":"External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder","volume":"61","author":"Nuhn","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0470","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0475","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.euo.2019.11.005","volume":"3","author":"Bruins","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0480","first-page":"149","article-title":"Palliative treatment of intractable hematuria in context of advanced bladder cancer: a systematic review","volume":"6","author":"Ghahestani","year":"2009","journal-title":"Urol J"},{"key":"10.1016\/j.eururo.2020.03.055_bib0485","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.juro.2010.04.008","article-title":"Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer","volume":"184","author":"Solsona","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0490","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s13566-017-0319-2","article-title":"Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalation","volume":"6","author":"Korpics","year":"2017","journal-title":"J Radiat Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0495","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.3109\/0284186X.2014.928418","article-title":"A comparison of morbidity following conformal versus intensity-modulated radiotherapy for urinary bladder cancer","volume":"53","author":"Sondergaard","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0500","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1002\/cncr.30719","article-title":"Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy","volume":"123","author":"Korpics","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0505","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.juro.2018.06.001","article-title":"Effectiveness of transurethral resection plus systemic chemotherapy as definitive treatment for muscle invasive bladder cancer in population level data","volume":"200","author":"Audenet","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0510","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2016.12.020","article-title":"Long-term outcomes after bladder-preserving tri-modality therapy for patients with muscle-invasive bladder cancer: an updated analysis of the Massachusetts General Hospital experience","volume":"71","author":"Giacalone","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0515","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0520","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","article-title":"Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy","volume":"72","author":"Krasnow","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0525","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bju.14109","article-title":"Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer","volume":"121","author":"Ritch","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.03.055_bib0530","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1002\/cncr.30900","article-title":"Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer","volume":"123","author":"Cahn","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0535","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0540","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.juro.2017.08.106","article-title":"Incidence, clinicopathological risk factors, management and outcomes of nonmuscle invasive recurrence after complete response to trimodality therapy for muscle invasive bladder cancer","volume":"199","author":"Sanchez","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0545","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","article-title":"Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0550","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S1470-2045(14)71160-X","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0555","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2015.64.1076","article-title":"Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer","volume":"34","author":"Galsky","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0560","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cncr.31952","article-title":"Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: does histologic subtype matter?","volume":"125","author":"Berg","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0565","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.seminoncol.2012.08.007","article-title":"New therapeutic challenges in advanced bladder cancer","volume":"39","author":"Bellmunt","year":"2012","journal-title":"Semin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0570","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0575","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2020.03.055_bib0580","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mdr156","article-title":"Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma","volume":"23","author":"Galsky","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0585","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1200\/JCO.1999.17.10.3173","article-title":"Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy","volume":"17","author":"Bajorin","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0590","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","article-title":"A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy","volume":"12","author":"Galsky","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0595","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0600","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/jco.2015.33.7_suppl.296","article-title":"Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: results of a phase IB study","volume":"33","author":"O\u2019Donnell","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0605","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2020.03.055_bib0610","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0615","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/S0140-6736(17)32365-6","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial","volume":"390","author":"Petrylak","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2020.03.055_bib0620","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2020.03.055_bib0625","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of & 2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0630","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","article-title":"Health-related quality-of-life analysis From KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer","volume":"36","author":"Vaughn","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0635","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2020.03.055_bib0640","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0645","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2020.03.055_bib0650","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/S1470-2045(19)30412-7","article-title":"Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Schuler","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0655","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-Programmed Death 1\/Programmed Death Ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0660","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0665","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2017.09.030","article-title":"The role of surgery in metastatic bladder cancer: a systematic review","volume":"73","author":"Abufaraj","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0670","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/bju.14047","article-title":"Impact of bladder cancer on health-related quality of life","volume":"121","author":"Smith","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2020.03.055_bib0675","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00345-019-02692-z","article-title":"Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomy","volume":"37","author":"Feuerstein","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0680","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.suronc.2016.05.027","article-title":"A systematic review and meta-analysis of quality of life outcomes after radical cystectomy for bladder cancer","volume":"25","author":"Yang","year":"2016","journal-title":"Surg Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0685","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejso.2015.10.001","article-title":"Systematic review and meta-analysis of non RCT\u2019s on health related quality of life after radical cystectomy using validated questionnaires: better results with orthotopic neobladder versus ileal conduit","volume":"42","author":"Cerruto","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0690","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.juro.2016.05.093","article-title":"Prospective evaluation of continence following radical cystectomy and orthotopic urinary diversion using a validated questionnaire","volume":"196","author":"Clifford","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0695","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00345-013-1219-8","article-title":"Urinary functional outcomes in female neobladder patients","volume":"32","author":"Bartsch","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0700","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.ijrobp.2016.08.023","article-title":"Quality of life in long-term survivors of muscle-invasive bladder cancer","volume":"96","author":"Mak","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2020.03.055_bib0705","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2010.05.041","article-title":"Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution?","volume":"58","author":"Giannarini","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0710","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.juro.2011.07.005","article-title":"Detection of asymptomatic recurrence during routine oncological followup after radical cystectomy is associated with improved patient survival","volume":"186","author":"Boorjian","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0715","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.eururo.2012.05.008","article-title":"Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature","volume":"62","author":"Soukup","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0720","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/MOU.0b013e32833cf10e","article-title":"Follow-up of patients after curative bladder cancer treatment: guidelines vs. practice","volume":"20","author":"Vrooman","year":"2010","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0725","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.urolonc.2017.11.007","article-title":"Urethral recurrence after radical cystectomy for urothelial carcinoma: a systematic review and meta-analysis","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0730","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.eururo.2016.09.035","article-title":"Systematic review on the fate of the remnant urothelium after radical cystectomy","volume":"71","author":"Gakis","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0735","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.juro.2012.08.017","article-title":"Upper urinary tract recurrence following radical cystectomy for bladder cancer: a meta-analysis on 13,185 patients","volume":"188","author":"Picozzi","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0740","doi-asserted-by":"crossref","first-page":"339.e1","DOI":"10.1016\/j.urolonc.2015.04.017","article-title":"Evaluation of current surveillance guidelines following radical cystectomy and proposal of a novel risk-based approach","volume":"33","author":"Stewart-Merrill","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2020.03.055_bib0745","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.2013.54.3173","article-title":"Risk of fracture after radical cystectomy and urinary diversion for bladder cancer","volume":"32","author":"Gupta","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382030230X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382030230X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:08:01Z","timestamp":1759583281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382030230X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":149,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S030228382030230X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}